Eli Lilly To Collaborate With OpenAI On Developing Antimicrobials To Treat Drug-Resistant Bacterial Infections

Reuters (6/25, Santhosh) reports, “Eli Lilly said on Tuesday it will collaborate with OpenAI to leverage its generative AI to develop antimicrobials that can be used to treat drug-resistant bacteria.” This collaboration “supports Lilly’s earlier commitment, which started in 2020 when it pledged $100 million to the AMR Action Fund.” Public health authorities “have raised concerns over the thin pipeline of new treatments to tackle antibiotic-resistant bacteria, which they say is not enough to combat the so-called superbugs.”